Vancomycin resistance: means of prevention, control, and treatment revisited.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2004 AND VI 39 AND IP 10
Results: 20
1
2
Cinacalcet: the first calcimimetic approved for secondary hyperparathyroidism.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
3
FDA to adopt new pediatric suicidality warning for antidepressant labelling.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 478
- Publication type:
- Article
4
Anxiety and sleep disorders.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 508
- Publication type:
- Article
5
Drug Watch.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 508
- Publication type:
- Article
6
New efforts to spur antimicrobial research gain momentum.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 507
- Publication type:
- Article
7
Purchasing pools yield more options, savings for states.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 507
- Publication type:
- Article
8
Government seeks posting of clinical trial results online.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 507
- Publication type:
- Article
9
'Roadmap' developed to prepare for and respond to pandemic.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 506
- Publication type:
- Article
10
Electronic database allows greater public access to studies.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 506
- Publication type:
- Article
11
FDA combats illegal WWW drug sales.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 506
- Publication type:
- Article
12
Vancomycin resistance: Means of prevention, control, and treatment revisited.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 490
- By:
- Publication type:
- Article
13
Cinacalcet.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 482
- By:
- Publication type:
- Article
14
Pregabalin demonstrates sustained efficacy in treating neuropathic pain.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 480
- Publication type:
- Article
15
Pipeline preview.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 476
- Publication type:
- Article
16
Rofecoxib voluntarily withdrawn from market due to cardiovascular risk.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 478
- Publication type:
- Article
17
New formulations.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 476
- Publication type:
- Article
18
New indications.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 476
- Publication type:
- Article
19
High-dose simvastatin fails to achieve primary end point in trial of ACS.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 480
- Publication type:
- Article
20
FDA actions in brief.
- Published in:
- Formulary, 2004, v. 39, n. 10, p. 477
- Publication type:
- Article